Methionine Loading in a Down's Syndrome Patient with Cerebral Infarction

Mudd SH Levy HL Ikovby F. Disorders in transsulfuration. In: Scriver CR Beaudet AL Sly WS Valle D , eds. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill, 1995: 1279–328.

Boers GHJ Smals AGH Trijbels FJM Fowler B Bakkeren JAJM Schoonderwaldt HC Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985; 313: 709–15.

Graham IM Daly LE Refsum HM Robinson K Brattström LE Ueland PM Plasma homocysteine as a risk factor for vascular disease. The European concerted action project. JAMA 1997; 277: 1775–81.

Frosst P Blom HJ Milos R Goyette P Sheppard CA Matthews RG A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111–3.

Tsai MY . Laboratory assessment of mild hyperhomocysteinemia as an independent risk factor for occlusive vascular diseases. Clin Chem 1996; 42: 492–3.

Chadefaux B Rethoré MO Raoul O Ceballos I Poissonnier M Gilgenkranz S Cystathionine beta synthase: Gene dosage effect in trisomy 21. Biochem Biophys Res Comm 1985; 128: 40–4.

Nakai H Watkins PC Byers MG Shows TB Tada K. Site specific mapping of chromosome 21 gene probes and the study of Down syndrome. Acta Paediatr Jpn 1987; 29: 510–2.

Domagala TB Libura M Szczeklik . Hyperhomocysteinemia following oral methionine load is associated with increased lipid peroxidation. Thromb Res 1997; 87: 411–6.

Scheurlen M. Morbus Meulengracht [in German]. Deutsche Medizinische Wochenschrift 1989; 114: 1767.

Sass JO Endres W. Quantitation of total homocysteine in human plasma by derivatization to its N(O,S)-propoxycarbonyl propyl ester and gas chromatography-mass spectrometry analysis. J Chromatogr A 1997; 776: 342–7.

Spinco Division of Beckman Instruments, Inc. The System 6300 High Performance Amino Acid Analyzer: Instruction Manual. Palo Alto: Beckman, Inc, 1982.

Jentzsch AM Bachmann H Fürst P Biesalski HK . Improved analysis of malondialdehyde in human body fluids. Free Radic Biol Med 1996; 20: 251–6.

Lejeune J Rethoré M-O de Blois M-C Peeters M Naffah J Megarbane A Amino acids and Trisomy 21 [in French]. Ann Genét 1992; 35: 8–13.

Chadefaux B Ceballos I Hamet M Coude M Poissonnier M Kamoun P Is absence of atheroma in Down syndrome due to decreased homocysteine levels? Lancet 1988; i: 741.

Brattström L Israelsson B Tengborn L Hultberg B. Homocysteine, factor VII and antithrombin III in subjects with different gene dosage for cystathionine β-synthase. J Inher Metab Dis 1989; 12: 475–82.

Hultberg B Andersson A Sterner G. Plasma homocysteine in renal failure. Clin Nephrol 1993; 40: 230–4.

Ueland PM Refsum H Stabler SP Malinow R Andersson A Allen RH . Total homocysteine in plasma or serum: Methods and clinical applications. Clin Chem 1993; 39: 1764–79.

Nehler MR Taylor LM Porter JM . Homocysteincmia as a risk factor for atherosclerosis: A review. Cardiovasc Pathol 1997; 6: 1–9.

Verhoef P Kok FJ Kluijtmans LAJ Blom HJ Refsum H Ueland PM The 677C→T mutation in the methylenetetrahydrofolate reductase gene: Associations with plasma total homocysteine levels and risk of coronary atherosclerotic disease. Atherosclerosis 1997; 132: 105–13.